One study found that combined treatment with anti-OX40/anti-CTLA4 reduced IRs expression on tumor specific CTLs and enhanced cytokine production (135), while others found that simultaneous blockade of TGFβ and PD-L1 increased CTL infiltration in tumors of patients with metastatic urothelial cancer (136). Here, TGFB1 is linked to neoplasm.